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Background 
Lung cancer screening might be a ‘teachable moment’ for smoking cessation or conversely could 
provide a ‘license to smoke’. Such effects should be considered in the overall benefits and harms of 
screening. Existing evidence of the impact of screening on smoking is mixed. 
Methods 
A randomised controlled trial of a blood autoantibody test (EarlyCDT-Lung) for the early detection of 
lung cancer was conducted in 12,210 smokers and ex-smokers in Scotland, UK. The test allowed risk 
stratification for targeting of a chest X-ray and repeat CT scans. Sub-samples of positive test (n = 
321), negative test (n = 361) and control (n = 350) participants completed questionnaires before 
screening, after receipt of blood test results and at 3, 6 and 12 months post-screening. They self-
reported smoking point prevalence, attempts to quit, number of cigarettes smoked per day and the 
Heaviness of Smoking Index. Multi-level regression analyses, adjusted for confounders, explored 
differences in smoking over time between screened and control arms and between positive test, 
negative test and control groups. 
Results 
Preliminary results show no statistically significant differences in smoking prevalence between the 
screened and control arms over time. There was a reduction in smoking prevalence of borderline 
statistical significance in the positive test group versus controls across all time points (OR 0.46, 95% 
CI 0.21-1.03). This difference reduced when assuming non-responding smokers were still smoking 
(OR 0.73, 95% CI 0.38-1.42). Significantly more smokers in the positive test group had recently 
attempted to stop smoking at 3 months compared to controls (OR 2.29, 95% CI 1.04-5.04). Positive 
test group smokers were significantly less likely to report smoking 20 or more cigarettes a day than 
controls across all time points (OR 0.32, 95% CI 0.14-0.69). Negative test group smokers were more 
likely to score moderate/high/very high on the Heaviness of Smoking Index compared to controls at 
6 months. This difference was statistically significant before adjusting for confounders but the 
adjusted model was no longer significant (OR 2.51, 95% CI 0.90-6.97).  
Conclusion 
There was no effect of lung cancer screening on smoking prevalence. The findings indicate a positive 
test result can be a teachable moment for smoking cessation. They also highlight the short term risk 
of heavier smoking after a negative test result. This is an important area for further research to 
ensure negative lung cancer screening test results do not inadvertently promote continued and 
heavier smoking. 
